GlassScriptPhysician profile
Rodney Lamont Bloom
NPI 1225005879
$2,709.41
in general payments reported to CMS, 2019-2025
27 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $438 · 2021: $494 · 2022: $519 · 2023: $280 · 2024: $385 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $897 · Education: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.11 |
| Education | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $380.30 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $274.30 | 2023-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $240.84 | 2019-2023 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $221.24 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $211.74 | 2020-2024 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $198.84 | 2019-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $179.65 | 2019-2023 | Eliquis |
| Amarin Pharma, INC. | $107.75 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $107.49 | 2019-2022 | |
| Eisai INC. | $100.15 | 2020-2025 | |
| Abbott Laboratories | $91.36 | 2020-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $81.39 | 2023-2025 | Gemtesa |
| Pfizer INC. | $68.27 | 2020-2024 | |
| Nestle Healthcare Nutrition INC. | $61.85 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $48.66 | 2024-2025 | Gvoke Hypopen |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.16 | 2019-2021 | |
| Astellas Pharma US INC | $45.19 | 2019-2020 | |
| Esperion Therapeutics, INC. | $40.55 | 2020-2021 | |
| Medtronic, INC. | $33.51 | 2024 | Minimed 780g, Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $33.39 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $30.73 | 2019 | |
| Medtronic Minimed, INC. | $26.94 | 2019 | |
| Dexcom, INC. | $22.94 | 2020 | |
| Insulet Corporation | $14.61 | 2024 | Omnipod |
| Allergan, INC. | $14.53 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.34 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.